Health
Canopy Biosciences develops spatial proteomics assay for COVID-19 – News-Medical.Net
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and…
-
Noosa News12 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News11 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Noosa News10 hours agoQueensland Drug and Alcohol Court provides sentencing options – Proctor
-
Business12 hours agoSolid superannuation gains continue to roll in